Literature DB >> 16391647

Frequency and amplitude of elevation of cerebrospinal fluid resting pressure by the Valsalva maneuver.

Lawrence Neville1, Robert A Egan.   

Abstract

BACKGROUND: Patients are referred to ophthalmologists to evaluate for papilledema when they are found to have elevated cerebrospinal fluid (CSF) pressure. However, some of these patients have no clinical history consistent with intracranial hyper-tension. We aimed to determine how often and how high patients with normal opening pressure could artificially elevate their CSF pressure to a pseudo-pathologic level by performing a Valsalva maneuver.
METHODS: We measured CSF pressure at rest and after a Valsalva maneuver in 15 consecutive normotensive patients referred for CSF analysis to determine the frequency and amplitude of elevation of pressure. Manometry was performed in the standard lateral decubitus position with legs and knees extended and abdomen relaxed and then again during a Valsalva maneuver with hip flexion and bearing down against a closed glottis.
RESULTS: All 15 normotensive patients elevated their CSF pressure to levels greater than 25 cm water. One patient reached a maximum pressure of 47 cm water.
INTERPRETATION: Artifactual elevation of CSF pressure may therefore occur frequently. Caution is advised before accepting a diagnosis of intracranial hypertension in those lacking this syndrome. These patients require repeat CSF pressure measurements to either verify or refute previous recordings.

Entities:  

Mesh:

Year:  2005        PMID: 16391647     DOI: 10.1016/S0008-4182(05)80100-0

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  20 in total

Review 1.  Cerebrospinal fluid and lumbar puncture: a practical review.

Authors:  Ben L C Wright; James T F Lai; Alexandra J Sinclair
Journal:  J Neurol       Date:  2012-01-26       Impact factor: 4.849

2.  Practice patterns and opening pressure measurements using fluoroscopically guided lumbar puncture.

Authors:  A S Abel; J R Brace; A M McKinney; A R Harrison; M S Lee
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

3.  The role of orbital ultrasonography in distinguishing papilledema from pseudopapilledema.

Authors:  S B Carter; M Pistilli; K G Livingston; D R Gold; N J Volpe; K S Shindler; G T Liu; M A Tamhankar
Journal:  Eye (Lond)       Date:  2014-09-05       Impact factor: 3.775

Review 4.  Dural sinus collapsibility, idiopathic intracranial hypertension, and the pathogenesis of chronic migraine.

Authors:  Roberto De Simone; Angelo Ranieri; Mattia Sansone; Enrico Marano; Cinzia Valeria Russo; Francesco Saccà; Vincenzo Bonavita
Journal:  Neurol Sci       Date:  2019-05       Impact factor: 3.307

Review 5.  Reference range of cerebrospinal fluid opening pressure in children: historical overview and current data.

Authors:  Robert A Avery
Journal:  Neuropediatrics       Date:  2014-05-27       Impact factor: 1.947

Review 6.  Interpretation of lumbar puncture opening pressure measurements in children.

Authors:  Robert A Avery
Journal:  J Neuroophthalmol       Date:  2014-09       Impact factor: 3.042

7.  Safety and Feasibility of Lumbar Cerebrospinal Fluid Pressure and Intraspinal Pressure Studies in Cervical Stenosis: A Case Series.

Authors:  Carl Moritz Zipser; José Miguel Spirig; José Aguirre; Anna-Sophie Hofer; Nikolai Pfender; Markus Hupp; Armin Curt; Mazda Farshad; Martin Schubert
Journal:  Acta Neurochir Suppl       Date:  2021

8.  Idiopathic intracranial hypertension.

Authors:  Michael Wall
Journal:  Neurol Clin       Date:  2010-08       Impact factor: 3.806

9.  Position-related variability of CSF opening pressure measurements.

Authors:  K M Schwartz; P H Luetmer; C H Hunt; A L Kotsenas; F E Diehn; L J Eckel; D F Black; V T Lehman; E P Lindell
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-11       Impact factor: 3.825

Review 10.  Idiopathic intracranial hypertension (pseudotumor cerebri).

Authors:  Michael Wall
Journal:  Curr Neurol Neurosci Rep       Date:  2008-03       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.